Plain-English translation of NCT06041477 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing two different schedules for treating advanced liver cancer using a combination of three approaches: chemotherapy delivered directly to the liver (called hepatic arterial perfusion chemotherapy), a targeted drug called lenvatinib, and an immunotherapy drug (a PD-1 antibody). The trial will compare whether giving all three treatments at the same time works better than starting with chemotherapy alone and adding the other medications later.
Many patients with advanced liver cancer cannot be operated on right away, but doctors believe that shrinking the tumor with the right combination of medications might make surgery possible. This trial is trying to find the best way to combine these three different types of treatment to give patients the best chance of becoming eligible for surgery and improving their outcomes.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. Both groups will receive chemotherapy infusions every 4 weeks through a special catheter placed in an artery that feeds your liver, combined with daily targeted medication and periodic immune therapy infusions. After 2 cycles (8 weeks), your tumor will be scanned to see how it's responding. Depending on your response, you may continue treatment, proceed to surgery, or be evaluated for other options. The full treatment phase lasts several months, with regular doctor visits, blood tests, and imaging scans to monitor your progress.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
China